Abbott receives FDA approval for its TactiFlex Duo Ablation Catheter

In September 2026, Abbott, a leader in global healthcare, announced the receipt of U.S. Food and Drug Administration (FDA) approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled, specifically designed to address challenging cases of atrial fibrillation (AFib) in patients. The approval of this dual-energy catheter, representing the latest generation of Abbott's cardiac ablation technology, signifies a crucial milestone in the company's ongoing commitment to enhancing therapies that assist physicians in treating complex heart rhythms with increased precision and flexibility. Abbott is poised to commence broader commercial adoption of this technology across the United States in the forthcoming weeks.

The FDA approval for the TactiFlex Duo is supported by data derived from Abbott's FlexPulse Investigational Device Exemption (IDE) study. Recent late-breaking data from this study were presented at the European Society of Cardiology (ESC) Congress 2026 and were simultaneously published in EP Europace, demonstrating favorable safety and effectiveness outcomes among patients with paroxysmal AFib, characterized by irregular heart rhythm episodes that can resolve spontaneously.

According to Uri Yaron, Senior Vice President of Abbott's Electrophysiology Business, "TactiFlex Duo represents a significant advancement as Abbott constructs the industry's most comprehensive electrophysiology portfolio. From diagnosis, mapping, and intracardiac ultrasound imaging to sophisticated treatments for the most intricate arrhythmias, Abbott is exceptionally positioned to support physicians at every stage of patient care. By continuously expanding our PFA portfolio and integrating innovative technologies across cardiovascular care, we are enabling physicians to navigate increasingly complex procedures while ensuring that more patients receive timely and appropriate care."

The FDA approval of the TactiFlex Duo further enhances Abbott's range of technologies aimed at aiding physicians in treating patients with cardiac arrhythmias. This marks the company’s fifth significant electrophysiology approval in a little over a year, following the Amulet 360™ and TactiFlex Duo CE Mark approvals in Europe earlier this year, as well as the U.S. and European approvals of the Volt™ PFA System in 2025.

Impact on Cardiovascular Devices Market

The global cardiovascular devices market size is estimated at USD 74.71 billion in 2025 and is anticipated to reach around USD 158.41 billion by 2035, expanding at a CAGR of 7.81% from 2026 to 2035.

According to Precedence Research, the global cardiovascular devices market is significantly driven by the growing prevalence of chronic cardiovascular diseases across the globe. For the approximately 10.5 million individuals in the U.S. who experience irregular, excessively fast, or slow heartbeats, timely treatment is essential, as AFib significantly elevates the risk of serious complications, including stroke. While many patients are managed with medications, others may require cardiac ablation, a minimally invasive procedure targeting the tissue responsible for the abnormal electrical signals within the heart.

TactiFlex Duo is Abbott’s latest advancement in ablation catheter technology, aimed at empowering physicians with enhanced flexibility in the treatment of AFib. This innovative technology permits the use of pulsed field ablation (PFA), radiofrequency (RF) energy, or a combination of both during procedures, thereby tailoring treatment to suit the individual needs of each patient.

Impact on the Electrophysiology Devices Market

The global electrophysiology devices market size accounted for USD 16.73 billion in 2026 and is predicted to reach around USD 55.43 billion by 2035 and is poised to grow at a CAGR of 14.31% from 2026 to 2035.

According to Precedence Research, the electrophysiology devices market is backed by healthcare leaders promising advancement in cardiovascular therapies. Following this, device manufacturers and providers are aligning with the leaders' efforts. The range of products and their regulatory approvals strengthen accessibility.

Dr. Atul Verma, Director of Cardiology at the McGill University Health Centre in Montreal, Canada, and an internationally recognized authority in pulsed field ablation technology, remarked, "Electrophysiology is rapidly advancing as physicians incorporate new technologies that enhance the safety and effectiveness of AFib treatment. The TactiFlex Duo offers greater procedural flexibility, and when combined with the high-resolution 3D visualization provided by Abbott's EnSite X mapping system, physicians are equipped with a suite of transformative tools to confidently address the needs of patients with complex AFib."

About Abbott

Abbott is a global leader in cardiovascular care, diabetes management, diagnostic testing, nutrition, pain and movement disorders, and more. In addition, through partnerships, Abbott raises awareness for chronic disease prevention and other issues that impact global health. Abbott operates in over 160 countries and sources from at least 62 suppliers worldwide. Abbott's products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip.